Latest news

• NICE rejects Imbruvica for non-Hodgkin’s lymphoma

  NICE rejects Imbruvica for non-Hodgkin’ s lymphoma. Draft guidance cites insufficient cost-effectiveness evidence for J&J’ s drug. ... drug. Imbruvica is used to treat Waldenstrom's macroglobulinaemia - a rare type of slow-growing non-Hodgkin's

• FDA clears Imbruvica as chemo alternative for first-line CLL

  mantle cell lymphoma (MCL) and the treatment of Waldenström's macroglobulinaemia. ... AbbVie and J&J's drug also achieved partial or complete responses in 82% of patients, compared to 35% of the chemotherapy group.

• AZ takes majority stake in cancer drug developer Acerta

  Acalabrutinib is a Bruton's tyrosine kinase (Btk) inhibitor in the same class as Janssen/Pharmacyclics/Abbvie's Imbruvica (ibrutinib) drug for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia, which ... This week it agreed a

• AZ confirms interest in Acerta takeover

  as a treatment for chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia. ... Analysts have speculated that AZ's interest in Acerta could draw other possible suitors out of the shadows.

• Imbruvica filed as first-line leukaemia therapy

  of Waldenström's macroglobulinaemia. ... Imbruvica is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor - licensed by Janssen from Pharmacyclics in 2011 in a deal valued at up to $975m.